Jump to content

Combination chemotherapies slow small cell lung cancer and

Recommended Posts

cancer of unknown primary site

http://www.medadnews.com/News/Index.cfm ... eid=295208

"The Oncologist" and "Cancer" publish Sarah Cannon Research Institute (SCRI) results

NASHVILLE, Tenn., Nov. 30, 2005 - Two Sarah Cannon Research Institute studies have identified new combination drug therapies that are more effective than traditional treatments for extensive stage small cell lung cancer and cancer of unknown primary site.

The combination of paclitaxel/carboplatin/etoposide as a first line treatment produces significant improvement in stopping progression of extensive stage small lung cancer. SCRI medical director Dr. F. Anthony Greco led the study comparing the combinations of paclitaxel paired with either topotecan or carboplatin and etoposide for overall response and time to progression. Results demonstrated that the combination of paclitaxel/carboplatin/etoposide produced a significant improvement in overall response rate and median time-to-progression, 7.6 months versus 5.5, and in the number of patients free from progression at one year.

The study, "Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial," is published in the October 2005 edition of The Oncologist.

The Nov. 1, 2005 edition of Cancer published the results of a phase II trial led by Dr. John D. Hainsworth, SCRI director of clinical research, to evaluate the activity of combination chemotherapy of gemcitabine and irinotecan in patients with previously treated cancer of unknown primary site.

Cancer of unknown primary site accounts for approximately 3 percent of all cancer diagnoses. For most of these patients, complete cancer eradication with the first round of chemotherapy is uncommon, requiring them to undergo additional therapy.

In the SCRI study, patients experienced increased efficacy with the combination chemotherapy of gemcitabine and irinotecan. Treatment-related side effects, particularly low blood counts, appear less severe than those produced by the taxane/platinum regimens frequently used in the first-line therapy of these patients.

Sarah Cannon Research Institute (SCRI) is one of the largest community-based research support programs in the United States offering management, regulatory and other support services for strategic investigator sites across the country. With a goal of advancing clinical research, SCRI works to provide greater access to oncology-related clinical trials in a community setting through a powerful network of 500 oncologists in 25 states.

# # #

Karen Litterer Baker

Atkinson Public Relations

Main: 615-320-7532

Direct: 615-963-1301


Contact: Anna Walker (615) 329-7216 Anna.Walker@scresearch.net

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.